AgingResearch.NewsJoin free

AAV9-SESTRIN2

Intervention

1 paper1 finding

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: American Diabetes Association and 4 more
  • Animals1

Outcomes

1

Cardiac ischemic tolerance

upin mice1

1 study

  1. AAV9-SESTRIN2 improves cardiac ischemic tolerance in mice.

    “the adeno-associated virus (AAV9)-Sestrin2 delivered to the aged hearts via a coronary delivery approach significantly rescued the ischemic tolerance of aged hearts.”

    AnimalsAged mice subjected to coronary artery occlusionAAV9-Sestrin2heart

    Sestrin2 prevents age-related intolerance to post myocardial infarction via AMPK/PGC-1α pathway

    Journal of molecular and cellular cardiology8 Jan 2018

Latest

Related